Cosentyx
Authorised
This medicine is authorised for use in the European Union
secukinumab
MedicineHumanAuthorised
Croatian is available via eTranslation, the European Commission's machine translation service.
Translate to Croatian | Important information about machine translation
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Cosentyx is a medicine that acts on the immune system (the body’s natural defences) and is used to treat the following conditions:
-
moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin) in adults and children from 6 years of age who need treatment with a systemic medicine (a medicine given by mouth or by injection);
-
psoriatic arthritis (inflammation of the joints associated with psoriasis) in adults when disease-modifying anti-rheumatic drugs (DMARDs) do not work well enough;
-
axial spondyloarthritis (inflammation of the spine causing back pain) in adults, including ankylosing spondylitis when X-ray shows the disease, and non-radiographic axial spondyloarthritis when there are clear signs of inflammation but X-ray does not show disease. It is used when conventional treatments do not work well enough;
-
two types of juvenile idiopathic arthritis (a form of arthritis in children), enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), in patients from 6 years of age when conventional therapy does not work well enough or is not tolerated. Cosentyx can be used on its own or in combination with methotrexate (a DMARD medicine);
-
hidradenitis suppurativa (acne inversa), a long-term skin disease that causes lumps, abscesses (collections of pus) and scarring on the skin, in adults. It is used to treat moderate-to-severe, active disease when conventional systemic treatments do not work well enough;
-
polymyalgia rheumatica, an inflammatory disease that causes muscle pain and stiffness, especially in the shoulders and hips. It is used in adults when medicines called corticosteroids are not working well enough or when their disease has returned while the dose of corticosteroids is reduced.
Cosentyx contains the active substance secukinumab.
Cosentyx can only be obtained with a prescription and treatment should be given under the supervision of a doctor with experience in diagnosing and treating the conditions for which Cosentyx is used.
Cosentyx is given by injection under the skin every week for 5 weeks and then once a month as maintenance treatment. For hidradenitis suppurativa, Cosentyx can also be given every two weeks for maintenance treatment.
Hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis or juvenile idiopathic arthritis usually improve within 16 weeks of starting treatment. If there is no improvement after 16 weeks, the doctor may decide to stop treatment. For polymyalgia rheumatica, Cosentyx is given together with a course of corticosteroids that is gradually reduced. Cosentyx can then be continued on its own. The dose may be increased depending on how well the treatment works.
Patients (or their carers) can give the injection if they have been trained to do so. For more information about using Cosentyx, see the package leaflet or contact your doctor or pharmacist.
The active substance in Cosentyx, secukinumab, is a monoclonal antibody, a type of protein, designed to attach to a protein called interleukin-17A. Interleukin-17A is involved in inflammation and other immune system processes that cause psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa and polymyalgia rheumatica. By attaching to interleukin-17A, secukinumab blocks its action and thereby reduces the activity of the immune system and symptoms of the disease.
Plaque psoriasis
Studies showed that Cosentyx is effective in treating psoriasis, psoriatic arthritis and axial spondyloarthritis, with patients showing greater improvements with Cosentyx than with placebo (a dummy treatment) or with a comparator medicine, etanercept.
In four psoriasis studies involving 2,403 adults, 79% of those on Cosentyx had a 75% reduction in their PASI score (a measure of disease severity and area of skin affected) after 12 weeks of treatment. This compares with 44% of those treated with etanercept and 4% of those receiving placebo. In addition, 65% of patients given Cosentyx had clear or nearly clear skin, compared with 27% of patients given etanercept and 2% of those given placebo.
In a study of severe psoriasis in 162 children from 6 years of age, around 80% of children given Cosentyx achieved a 75% reduction in their PASI score and around 70% had skin that was clear or almost clear of psoriasis after 12 weeks. This compares with 66% and 36%, respectively, for patients treated with etanercept and 15% and 6% for patients treated with placebo.
Psoriatic arthritis
In a study of 397 patients with psoriatic arthritis, between 51% and 54% of patients on the approved doses of Cosentyx achieved a 20% reduction in their ACR score (painful, swollen joints and other symptoms) after 24 weeks. This compares with 15% of patients on placebo.
Ankylosing spondylitis
In a study of 219 adults with ankylosing spondylitis, 61% of patients given the approved dose of Cosentyx had a 20% reduction in ASAS scores (back pain, morning stiffness and other symptoms) after 16 weeks, compared with 28% of patients on placebo. In another study involving 555 adults with non-radiographic axial spondyloarthritis, 41% of patients given the approved dose of Cosentyx had a 40% reduction in ASAS scores after 16 weeks, compared with 29% of patients on placebo.
Juvenile idiopathic arthritis
In a study involving 75 children between 2 and 17 years of age with active ERA or JPsA, fewer patients treated with Cosentyx had a flare-up of their condition compared with those given placebo (10 versus 21). As the study included only a few children younger than six years of age, data from this age group were inconclusive and Cosentyx is therefore to be used from the age of six.
Hidradenitis suppurativa
In two studies involving 1,084 adults with moderate to severe hidradenitis suppurativa, 44% of patients who were given Cosentyx achieved at least 50% reduction in abscesses and nodules after 16 weeks, without any increase in the number of abscesses or fistulas (abnormal passageway). The proportion of patients given placebo who achieved this response was 32%.
Polymyalgia rheumatica
In one study involving 381 adults with polymyalgia rheumatica who had experienced at least one relapse (worsening) of their condition while their corticosteroid dose was being reduced, 41% of adults given the higher dose of Cosentyx and around 41% of those given a lower dose had sustained remission by week 12 through to week 52. This meant that they had no signs or symptoms of polymyalgia rheumatica requiring additional treatment and were not newly diagnosed with giant cell arteritis (a related inflammatory condition affecting large and medium-sized arteries) requiring such treatment. This compared with 20% of adults given placebo. In the study, all adults had their dose of corticosteroids gradually reduced over 24 weeks.
Studies carried out with Cosentyx are described in more detail in the medicine’s assessment reports.
For the full list of side effects and restrictions of Cosentyx, see the package leaflet.
The most common side effects with Cosentyx (which may affect more than 1 in 10 people) include upper respiratory tract (nose and throat) infections with nasopharyngitis (inflammation of the nose and throat) and rhinitis (blocked or runny nose).
Because Cosentyx can increase the risk of infection, it must not be given to patients with serious active (ongoing) infections such as tuberculosis.
In studies, Cosentyx was of substantial clinical benefit in patients with psoriasis, psoriatic arthritis, axial spondyloarthritis, enthesitis-related arthritis and juvenile psoriatic arthritis. Cosentyx has been shown to provide a relevant treatment effect in adults with moderate to severe hidradenitis suppurativa, a disease that has few systemic treatment options. Cosentyx was effective at keeping adults with polymyalgia rheumatica free of signs and symptoms of the disease for up to one year when their disease was not adequately controlled with corticosteroids or returned as the corticosteroid dose was reduced.
The safety profile was considered reassuring, with the main concern related to mild infections. The European Medicines Agency therefore decided that Cosentyx’s benefits are greater than its risks and it can be authorised for use in the EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cosentyx have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Cosentyx are continuously monitored. Suspected side effects reported with Cosentyx are carefully evaluated and any necessary action taken to protect patients.
Cosentyx received a marketing authorisation valid throughout the EU on 15 January 2015.
Product information
Latest procedure affecting product information:VR/0000326984
19/10/2026
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Cosentyx
- Active substance
- secukinumab
- International non-proprietary name (INN) or common name
- secukinumab
- Therapeutic area (MeSH)
- Arthritis, Psoriatic
- Psoriasis
- Spondylitis, Ankylosing
- Anatomical therapeutic chemical (ATC) code
- L04AC10
Pharmacotherapeutic group
ImmunosuppressantsTherapeutic indication
Plaque psoriasis
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.
Hidradenitis suppurativa (HS)
Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.
Psoriatic arthritis
Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.
Axial spondyloarthritis (axSpA)
Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
Non-radiographic axial spondyloarthritis (nr-axSpA)
Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).
Juvenile idiopathic arthritis (JIA)
Enthesitis-related arthritis (ERA)
Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
Juvenile psoriatic arthritis (JPsA)
Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
Polymyalgia rheumatica (PMR)
Cosentyx is indicated for the treatment of polymyalgia rheumatica in adults who have had an inadequate response to glucocorticoids or who experience a relapse during glucocorticoid taper.
Assessment history
News on Cosentyx
This page was last updated on